Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476619 · ClinicalTrials.gov registry record · Phase 4
Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT00476619 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants.
The verdict
NCT00476619, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
Full Title: A Randomized Controlled Trial of Procrit for the Prevention of Acute Renal Failure in Patients Receiving Intravenous Contrast Primary Objective: To evaluate the efficacy of a one-time dose of intravenous erythropoietin administration in the prevention or attenuation of contrast-induced acute renal failure. Secondary Objectives: To evaluate serum and urinary markers of renal injury, including KIM-1, BMP-7, and TGF-b, along with other biomarkers, in subjects receiving intravenous contrast and correlate their expression with clinical outcomes Study Design: Prospective, multi-centered, randomized, double blind, placebo controlled trial of a one-time dose of EPO. Subjects will be followed for seven days or until hospital discharge, whichever is longer. Total estimated study duration 3 years.
Interventions
- DRUG erythropoeitin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476619
The ClinicalTrials.gov registry entry for NCT00476619 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which erythropoeitin is the first listed.
NCT00476619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00476619 about?
NCT00476619 is a clinical study titled "Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial". Full Title: A Randomized Controlled Trial of Procrit for the Prevention of Acute Renal Failure in Patients Receiving Intravenous Contrast Primary Objective: To evaluate the efficacy of a one-time dose of intravenous erythropoietin administration in the prevention or attenuation of contrast-induced ...
What is the current status of trial NCT00476619?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2004-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00476619?
The interventions under investigation include: erythropoeitin (DRUG).
Who is sponsoring clinical trial NCT00476619?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.